Recursion Pharmaceuticals' Plunge Raises Questions About AI's Dark Side The recent stock price drop of Recursion Pharmaceuticals (RXRX) to a new 52 week low has sent shockwaves through the AI sector, leaving many investors wondering if the company is indeed oversold.
RXRX's AI native drug discovery platform and pipeline show promising progress in various therapeutic areas, but its plummeting share price raises important questions about the viability of relying on AI for drug development.
The intersection of AI and biotechnology has significant potential to revolutionize the pharmaceutical industry. However, RXRX's struggles highlight the risks involved in this complex field.